The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
Recent Content
- (no title)
- Atebimetinib nearly doubles 1-year survival in pancreatic cancer study
- Diagnosis, risk stratification and management of smouldering multiple myeloma
- The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials
- Temporal trends in progression risk in smoldering myeloma: a systematic review
- Infection risks associated with daratumumab-containing regimens in multiple myeloma: a systematic review and meta-analysis
- Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis
- (no title)
- (no title)
- (no title)